PTC Therapeutics acquired the BLA-stage ST-920 gene therapy from Sangamo, targeting a Q4 2026 FDA submission for accelerated approval. The deal expands PTC's portfolio into gene therapy for Fabry disease.
PTC Therapeutics acquired the BLA-stage ST-920 gene therapy from Sangamo, targeting a Q4 2026 FDA submission for accelerated approval. The deal expands PTC's portfolio into gene therapy for Fabry disease.